Draft:Alimetry Limited

Alimetry Limited is a medical device company that designs, manufactures, and distributes wearable digital health products that aid in the diagnosis of gastric disorders. The company's first product is called Gastric Alimetry.

History
Alimetry Limited was established in 2019 by Professor Gregory O'Grady and Dr. Armen Gharibans, as a spin-off from the University of Auckland. Alimetry was founded on research in gastrointestinal electrophysiology, and the company has won awards including the Excellence in Innovation Award at the New Zealand International Business Awards, Most Innovative Hi-Tech Hardware Product, Most Innovative Hi-Tech Creative Technology Solution, and Most Innovative Deep Tech Solution at the New Zealand Hi-Tech Awards. The company focuses on the non-invasive assessment of electrophysiology, motility patterns, and symptom profiles in patients with chronic gastrointestinal symptoms.

Gastric Alimetry
The Gastric Alimetry System is a medical device to aid in the diagnosis of various gastric disorders. The system incorporates a wearable device employing body surface gastric mapping technology derived from Electrogastrogram research. It captures electrophysioloigcal data from the stomach alongside patient-reported symptoms, including nausea, vomiting, abdominal pain, and bloating.

Technology
The Gastric Alimetry device employs patented body surface gastric mapping technology, utilizing a sensor array and connector to detect electrophysiological data from the stomach. Validated in both a porcine animal model, and human participants, this technology has demonstrated it can accurately assess gastric function non-invasively.

Clinical Research
Some key evidence papers include:


 * Gastric dysfunction in patients with chronic nausea and vomiting syndromes defined by a noninvasive gastric mapping device (2022)
 * This study mapped 43 patients with chronic nausea and vomiting syndromes with 43 matched controls. The results validated the Gastric Alimetry technology in patients with chronic nausea and vomiting by showing that abnormalities could be detected by the device. Two subtypes of nausea and vomiting symptoms with indistinguishable symptoms could be detected.
 * Normative Values for Body Surface Gastric Mapping Evaluations of Gastric Motility Using Gastric Alimetry: Spectral Analysis (2023)
 * Normative reference intervals for key metrics of gastric motility were established in this paper. The metrics are; Principal Gastric Frequency, Gastric Alimetry Rhythm Index, BMI-adjusted amplitude, and Fed:Fasted Amplitude Ratio.
 * Comparison of Gastric Alimetry® body surface gastric mapping versus electrogastrography spectral analysis (2023)
 * Gastric Alimetry was directly compared to electrogastrography in a cohort of 178 participants. Body surface gastric mapping was shown to perform substantially better than EGG across group-level differences, symptom correlations, and patient-level classifications.

Regulatory Approvals, Market, and Applications
Gastric Alimetry holds regulatory approvals for use in the UK, New Zealand, and the USA, receiving FDA approval in 2022. In 2022, Alimetry's US-based subsidiary called Alimetry Inc., was established and it is headquartered in Minneapolis, MN. The company has obtained ISO13485 registration, ensuring compliance with international standards for medical device manufacturers.

Awards, Recognition, and Grants
Alimetry was awarded the inaugural Ārohia Trailblazer Grant from Callaghan Innovation, the Excellence in Innovation Award at the New Zealand International Business Awards 2023, and three awards at the New Zealand Hi-Tech Awards in 2022. Alimetry was also a finalist in the the Asia Pacific MedTech Innovator competition, and won the Medtronic APAC Innovation Challenge. Additionally, Alimetry has been recognized for its design excellence, receiving awards at the Best Design Awards NZ and the Good Design Awards Australia.

Investors
Alimetry secured its initial funding round in December 2020, followed by a Series A raise of NZ$16.3 million in March 2022. The Series A round was led by Movac with support from existing investors such as UniServices, IP Group, Matū Karihi, and K1W1.